V-5 Immunitor: Interim Phase IIb data

Interim data from 55 evaluable patients in the double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard of

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE